Pfizer Scraps Weight-Loss Pill Due to Liver Injury Concerns

Pfizer's Weight-Loss Pill Development Halted

• ❌ Pfizer has decided to scrap the development of its once-daily GLP-1 pill for weight loss.
• ⚠️ This decision follows a reported liver injury in a patient participating in the drug's clinical trial.

Market Context and Future Prospects

• 📈 Pfizer aimed to be a key player in the rapidly growing weight loss market, projected to reach $150 billion.
• 💡 Despite this setback, Pfizer remains committed to developing innovative medicines and has another pill targeting the GIPR hormone in phase 2 trials.
• 🎯 Competitors like Eli Lilly and Novo Nordisk are leading the market with their weight loss injections and are also developing pills in late-stage trials.

FDA Warning on Counterfeit Drugs

• 🚨 The FDA has issued a warning regarding counterfeit Ozempic now available on the market from unauthorized sources.
• 🔍 Counterfeit products have a specific lot number (P0362) and serial number prefix (517).
• 🔒 Patients are strongly advised to purchase medications only from licensed pharmacies.
• 🔬 The FDA and the maker of Ozempic are currently testing these counterfeit products to assess their safety.